PMID- 23913854
OWN - NLM
STAT- MEDLINE
DCOM- 20150112
LR  - 20211021
IS  - 1552-4965 (Electronic)
IS  - 1549-3296 (Print)
IS  - 1549-3296 (Linking)
VI  - 102
IP  - 7
DP  - 2014 Jul
TI  - Immunotherapy with injectable hydrogels to treat obstructive nephropathy.
PG  - 2173-80
LID - 10.1002/jbm.a.34902 [doi]
AB  - Hydrogels are gaining attention as injectable vehicles for delivery of 
      therapeutics for a range of applications. We describe self-assembling and 
      injectable Dock-and-Lock hydrogels for local delivery of interleukin-10 (IL-10) 
      to abate the progression of inflammation and fibrosis that leads to chronic 
      kidney disease. As monitored with a fluorescent tag, hydrogels degraded within a 
      few days in vitro and matched IL-10 release profiles; however, hydrogels remained 
      in the kidney for up to 30 days in vivo. A unilateral ureteral obstruction (UUO) 
      mouse model was used to investigate in vivo outcomes after hydrogel injection and 
      IL-10 delivery. Eight groups were investigated (7, 21, 35 days, n = 4): healthy, 
      sham, healthy injected with mouse serum albumin (MSA), healthy + hydrogel, UUO, 
      UUO + IL-10, UUO + hydrogel, UUO + hydrogel/IL-10. 15 muL of IL-10, hydrogel, or 
      hydrogel/IL-10 was injected under the renal capsule 3 days after the UUO. 
      Immunohistochemistry (IHC) was performed on paraffin sections to identify 
      macrophages and apoptotic cells and trichrome staining was used to evaluate 
      fibrosis. There were no significant differences in inflammatory markers between 
      all control groups. With hydrogel delivery, macrophage infiltration and apoptosis 
      were significantly reduced at days 21 and 35 compared to untreated animals. By 
      day 35, IL-10 delivery via hydrogel reduced macrophage infiltration and apoptosis 
      more than IL-10 injection alone. Fibrosis was decreased by day 35 in all 
      treatment groups. This work supports the use of hydrogel delivery of IL-10 to 
      treat chronic kidney disease.
CI  - (c) 2013 Wiley Periodicals, Inc.
FAU - Soranno, Danielle E
AU  - Soranno DE
AD  - Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, 
      Pennsylvania.
FAU - Lu, Hoang D
AU  - Lu HD
FAU - Weber, Heather M
AU  - Weber HM
FAU - Rai, Reena
AU  - Rai R
FAU - Burdick, Jason A
AU  - Burdick JA
LA  - eng
GR  - T32 DK007378/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20130808
PL  - United States
TA  - J Biomed Mater Res A
JT  - Journal of biomedical materials research. Part A
JID - 101234237
RN  - 0 (Hydrogels)
RN  - 130068-27-8 (Interleukin-10)
SB  - IM
MH  - Animals
MH  - Apoptosis
MH  - Disease Models, Animal
MH  - *Hydrogels
MH  - *Immunotherapy
MH  - Interleukin-10/metabolism
MH  - Kidney Diseases/metabolism/pathology/*therapy
MH  - Macrophages/cytology
MH  - Mice
MH  - Mice, Inbred BALB C
PMC - PMC3928238
MID - NIHMS547284
OTO - NOTNLM
OT  - drug delivery
OT  - hydrogel
OT  - inflammation
OT  - kidney
OT  - nephropathy
EDAT- 2013/08/06 06:00
MHDA- 2015/01/13 06:00
PMCR- 2015/07/01
CRDT- 2013/08/06 06:00
PHST- 2013/06/29 00:00 [received]
PHST- 2013/07/25 00:00 [accepted]
PHST- 2013/08/06 06:00 [entrez]
PHST- 2013/08/06 06:00 [pubmed]
PHST- 2015/01/13 06:00 [medline]
PHST- 2015/07/01 00:00 [pmc-release]
AID - 10.1002/jbm.a.34902 [doi]
PST - ppublish
SO  - J Biomed Mater Res A. 2014 Jul;102(7):2173-80. doi: 10.1002/jbm.a.34902. Epub 
      2013 Aug 8.